GBIO | Generation Bio Co. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.2900 - 1.4600
52 Week Range	1.1000 - 4.65
Beta	2.53
Implied Volatility	348.65%
IV Rank	70.38%
Day's Volume	182,347
Average Volume	123,057
Shares Outstanding	66,792,800
Market Cap	90,170,280
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-06-12

Valuation
Profitability
Growth
Health
P/E Ratio	-0.62
Forward P/E Ratio	N/A
EPS	-2.19
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	174
Country	USA
Website	GBIO

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

GBIO's peers: ADCT, APRE, BCLI, CDXS, CLSD, GLUE, NKTX, LYEL, SANA, KRON, ERAS, CCCC, EWTX, IPSC, PASG, FIXX, STOK, NUVB, STTK, IFRX, IMUX, KPTI, LGVN, LTRN, LVTX, MDWD, MGTX, MTNB, NRIX, PSTX, SEER, SYBX, URGN, VTVT, XBIT, YMAB, IVVD, MLEC, GRI

*Chart delayed

Analyzing fundamentals for GBIO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see GBIO Fundamentals page.

Watching at GBIO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on GBIO Technicals page.